Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden
Authors:
Open Access
- 1 October 2017
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 3 (10) , 1393-1398
Abstract
Low-risk prostate cancer has a prolonged natural history and can be safely managed with active surveillance and selective, deferred use of curative treatment. Despite this, recent US studies have reported that most low-risk prostate cancer is managed with immediate curative treatment,1 often reducing quality of life. Moreover, a recent modeling study showed that prostate cancer screening is generally not cost-effective based on current US treatment patterns but would be cost-effective if low-risk prostate cancer were managed conservatively.2 Although Sweden does not have a national screening program, more than 50% of Swedish men aged 55 to 69 years have been exposed to prostate-specific antigen (PSA) screening.3,4Keywords
This publication has 14 references indexed in Scilit:
- Trends in initial management of prostate cancer in New HampshireCancer Causes & Control, 2015
- Upper limit of cancer extent on biopsy defining very low‐risk prostate cancerBJU International, 2015
- Five-year Nationwide Follow-up Study of Active Surveillance for Prostate CancerEuropean Urology, 2015
- Contemporary Use of Initial Active Surveillance Among Men in Michigan with Low-risk Prostate CancerEuropean Urology, 2015
- Capture rate and representativity of The National Prostate Cancer Register of SwedenActa Oncologica, 2014
- Population Based Study of Use and Determinants of Active Surveillance and Watchful Waiting for Low and Intermediate Risk Prostate CancerJournal of Urology, 2013
- Prostate-specific Antigen (PSA) Testing Is Prevalent and Increasing in Stockholm County, Sweden, Despite No Recommendations for PSA Screening: Results from a Population-based Study, 2003–2011European Urology, 2013
- Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0International Journal of Epidemiology, 2012
- Uptake of prostate‐specific antigen testing for early prostate cancer detection in SwedenInternational Journal of Cancer, 2010
- Mortality results from the Göteborg randomised population-based prostate-cancer screening trialThe Lancet Oncology, 2010